(KURA) Kura Oncology - Overview
Stock: Ziftomenib, Tipifarnib, KO-2806
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 59.2% |
| Relative Tail Risk | -9.64% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.05 |
| Alpha | -28.81 |
| Character TTM | |
|---|---|
| Beta | 0.973 |
| Beta Downside | 0.719 |
| Drawdowns 3y | |
|---|---|
| Max DD | 76.46% |
| CAGR/Max DD | -0.19 |
Description: KURA Kura Oncology December 26, 2025
Kura Oncology Inc. (NASDAQ:KURA) is a clinical-stage biopharma focused on targeted cancer therapies. Its pipeline centers on three investigational agents: ziftomenib, a selective menin-KMT2A inhibitor aimed at genetically defined acute leukemias (AML and ALL); tipifarnib, an oral farnesyl-transferase inhibitor being tested in combination with alpelisib for PIK3CA-driven head-and-neck squamous cell carcinoma (HNSCC); and KO-2806, another farnesyl-transferase inhibitor paired with Mirati’s KRAS G12C blocker adagrasib in non-small-cell lung cancer (NSCLC). The company leverages collaborations with Novartis (tipifarnib + alpelisib), Kyowa Kirin (menin inhibitor development and commercialization) and Mirati (KO-2806 + adagrasib). Headquarters are in San Diego, California.
As of the most recent 10-Q (Q2 2025), Kura reported cash and cash equivalents of roughly $150 million, giving it an estimated 12-month runway at current burn (~$12 million per month). R&D expense accelerated to $38 million year-to-date, reflecting the initiation of Phase 2 trials for ziftomenib and the tipifarnib-alpelisib combination. The biotech sector’s funding environment remains supportive, with venture capital raising up ≈ 15 % YoY in 2024, while FDA’s “oncology priority review” pathway has shortened approval timelines for novel mechanisms of action, a macro-driver that could benefit Kura’s menin-targeted approach.
For a deeper quantitative assessment, see the ValueRay page on KURA.
Piotroski VR‑10 (Strict, 0-10) 2.0
| Net Income: -216.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.13 > 0.02 and ΔFCF/TA 48.14 > 1.0 |
| NWC/Revenue: 480.0% < 20% (prev 33.3k%; Δ -32.8k% < -1%) |
| CFO/TA 0.14 > 3% & CFO 87.8m > Net Income -216.9m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 5.12 > 1.5 & < 3 |
| Outstanding Shares: last quarter (87.6m) vs 12m ago 0.80% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 18.44% > 50% (prev 0.27%; Δ 18.18% > 0%) |
| Interest Coverage Ratio: -136.5 > 6 (EBITDA TTM -220.8m / Interest Expense TTM 1.57m) |
Altman Z'' -5.81
| A: 0.77 (Total Current Assets 620.7m - Total Current Liabilities 121.3m) / Total Assets 649.4m |
| B: -1.68 (Retained Earnings -1.09b / Total Assets 649.4m) |
| C: -0.38 (EBIT TTM -214.2m / Avg Total Assets 564.1m) |
| D: -2.68 (Book Value of Equity -1.09b / Total Liabilities 406.8m) |
| Altman-Z'' Score: -5.81 = D |
Beneish M 1.00
| DSRI: 0.17 (Receivables 39.2m/2.80m, Revenue 104.0m/1.27m) |
| GMI: 0.34 (GM 96.50% / 32.44%) |
| AQI: 1.23 (AQ_t 0.02 / AQ_t-1 0.02) |
| SGI: 81.91 (Revenue 104.0m / 1.27m) |
| TATA: -0.47 (NI -216.9m - CFO 87.8m) / TA 649.4m) |
| Beneish M-Score: 53.36 (Cap -4..+1) = D |
What is the price of KURA shares?
Over the past week, the price has changed by -3.57%, over one month by -17.92%, over three months by -22.93% and over the past year by -11.22%.
Is KURA a buy, sell or hold?
- StrongBuy: 10
- Buy: 3
- Hold: 2
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the KURA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 32.6 | 315.7% |
| Analysts Target Price | 32.6 | 315.7% |
| ValueRay Target Price | 7.2 | -8.3% |
KURA Fundamental Data Overview February 02, 2026
P/B = 2.9132
Revenue TTM = 104.0m USD
EBIT TTM = -214.2m USD
EBITDA TTM = -220.8m USD
Long Term Debt = 5.34m USD (from longTermDebt, last quarter)
Short Term Debt = 5.77m USD (from shortTermDebt, last quarter)
Debt = 19.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -75.8m USD (from netDebt column, last quarter)
Enterprise Value = 176.4m USD (706.6m + Debt 19.5m - CCE 549.7m)
Interest Coverage Ratio = -136.5 (Ebit TTM -214.2m / Interest Expense TTM 1.57m)
EV/FCF = 2.12x (Enterprise Value 176.4m / FCF TTM 83.1m)
FCF Yield = 47.12% (FCF TTM 83.1m / Enterprise Value 176.4m)
FCF Margin = 79.89% (FCF TTM 83.1m / Revenue TTM 104.0m)
Net Margin = -208.5% (Net Income TTM -216.9m / Revenue TTM 104.0m)
Gross Margin = unknown ((Revenue TTM 104.0m - Cost of Revenue TTM 3.64m) / Revenue TTM)
Tobins Q-Ratio = 0.27 (Enterprise Value 176.4m / Total Assets 649.4m)
Interest Expense / Debt = 2.02% (Interest Expense 393.0k / Debt 19.5m)
Taxrate = 21.0% (US default 21%)
NOPAT = -169.2m (EBIT -214.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 5.12 (Total Current Assets 620.7m / Total Current Liabilities 121.3m)
Debt / Equity = 0.08 (Debt 19.5m / totalStockholderEquity, last quarter 242.5m)
Debt / EBITDA = 0.34 (negative EBITDA) (Net Debt -75.8m / EBITDA -220.8m)
Debt / FCF = -0.91 (Net Debt -75.8m / FCF TTM 83.1m)
Total Stockholder Equity = 331.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -38.45% (Net Income -216.9m / Total Assets 649.4m)
RoE = -65.42% (Net Income TTM -216.9m / Total Stockholder Equity 331.5m)
RoCE = -63.60% (EBIT -214.2m / Capital Employed (Equity 331.5m + L.T.Debt 5.34m))
RoIC = -49.61% (negative operating profit) (NOPAT -169.2m / Invested Capital 341.1m)
WACC = 9.29% (E(706.6m)/V(726.0m) * Re(9.50%) + D(19.5m)/V(726.0m) * Rd(2.02%) * (1-Tc(0.21)))
Discount Rate = 9.50% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 6.46%
[DCF Debug] Terminal Value 74.23% ; FCFF base≈83.1m ; Y1≈86.7m ; Y5≈100.0m
Fair Price DCF = 16.87 (EV 1.39b - Net Debt -75.8m = Equity 1.47b / Shares 87.0m; r=9.29% [WACC]; 5y FCF grow 4.64% → 2.90% )
EPS Correlation: 5.19 | EPS CAGR: 23.20% | SUE: 1.21 | # QB: 1
Revenue Correlation: 74.28 | Revenue CAGR: 52.37% | SUE: -1.39 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.89 | Chg30d=-0.098 | Revisions Net=+1 | Analysts=5
EPS next Year (2026-12-31): EPS=-2.60 | Chg30d=-0.331 | Revisions Net=-2 | Growth EPS=-4.7% | Growth Revenue=+55.7%